Compare Nasdaq100 ETF (QQQ) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Tilray Brands Inc — how do they compare? Nasdaq100 ETF trades at $751.26 (market cap $506.92B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Nasdaq100 ETF is far larger — about 955.5× Tilray Brands Inc's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 162 Days and Tilray Brands Inc for 31 Days on average.
| QQQ | TLRY | |
|---|---|---|
Market Cap | $506.92B | $530.54M |
Volume | 48,326,518 | 9,099,075 |
52-Week High | $759.66 | $21.00 |
52-Week Low | $558.34 | $3.57 |
Typical Hold Time | 162 Days | 31 Days |
Sector | — | Health |
Enterprise Value | — | $684.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $751.27, down 0.85% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong institutional interest but faces mixed analyst sentiment with a 50% buy and 50% sell rating. Recent news highlights ongoing comparisons with lower-fee alternatives like QQQM and VOO, while AI-driven tech exposure remains a key growth driver amid market volatility concerns.
The outlook for QQQ hinges on tech sector performance and interest rate sensitivity. Opportunities include AI innovation and Nasdaq 100 leadership, but risks involve high concentration in tech stocks, valuation pressures, and macroeconomic headwinds. Investor sentiment is divided, reflecting the ETF's growth potential against fee competitiveness and market cyclicality.
TLRY trades at $3.54, down 4.71% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows negative technical momentum with consecutive earnings misses and widening losses despite revenue growth. Recent financials reveal a net loss of $2.19B for 2025, though analyst consensus maintains a $65.01 price target with 25% buy ratings. Business developments include new product launches and leadership changes under Tilray's expanded beverage portfolio.
Outlook remains challenged by profitability concerns and high debt, but potential cannabis regulatory shifts could catalyze recovery. Investment opportunity hinges on execution improvement and market expansion, while risks include sustained cash burn and competitive pressures in the cannabis sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
